chr11-94470486-G-C
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_005591.4(MRE11):āc.1002C>Gā(p.Ser334Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00247 in 1,612,802 control chromosomes in the GnomAD database, including 80 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ).
Frequency
Consequence
NM_005591.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MRE11 | NM_005591.4 | c.1002C>G | p.Ser334Arg | missense_variant | 9/20 | ENST00000323929.8 | NP_005582.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MRE11 | ENST00000323929.8 | c.1002C>G | p.Ser334Arg | missense_variant | 9/20 | 1 | NM_005591.4 | ENSP00000325863 | P3 | |
MRE11 | ENST00000323977.7 | c.1002C>G | p.Ser334Arg | missense_variant | 9/19 | 1 | ENSP00000326094 | |||
MRE11 | ENST00000407439.7 | c.1011C>G | p.Ser337Arg | missense_variant | 9/20 | 2 | ENSP00000385614 | |||
MRE11 | ENST00000393241.8 | c.1002C>G | p.Ser334Arg | missense_variant | 9/20 | 5 | ENSP00000376933 | A1 |
Frequencies
GnomAD3 genomes AF: 0.0128 AC: 1947AN: 152012Hom.: 43 Cov.: 32
GnomAD3 exomes AF: 0.00353 AC: 886AN: 251082Hom.: 20 AF XY: 0.00242 AC XY: 329AN XY: 135714
GnomAD4 exome AF: 0.00139 AC: 2036AN: 1460672Hom.: 37 Cov.: 31 AF XY: 0.00120 AC XY: 875AN XY: 726656
GnomAD4 genome AF: 0.0129 AC: 1955AN: 152130Hom.: 43 Cov.: 32 AF XY: 0.0124 AC XY: 919AN XY: 74354
ClinVar
Submissions by phenotype
Ataxia-telangiectasia-like disorder 1 Benign:4
Benign, criteria provided, single submitter | clinical testing | KCCC/NGS Laboratory, Kuwait Cancer Control Center | Jul 07, 2023 | - - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Benign, criteria provided, single submitter | clinical testing | Counsyl | Jun 03, 2016 | - - |
Benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 16, 2023 | - - |
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 06, 2016 | Variant summary: The MRE11A c.1002C>G variant affects a non-conserved nucleotide, resulting in amino acid change from Ser to Arg. 2/3 in-silico tools predict this variant to be benign (SNPs&GO and Mutation Taster not captured due to low reliability index). This variant was found in 502/120966 control chromosomes (8 homozygotes) at a frequency of 0.0041499, which is about 66 times the maximal expected frequency of a pathogenic MRE11A allele (0.0000625), highly suggesting this variant is benign. In addition, one clinical laboratory classified this variant as benign. Taken together, this variant was classified as benign. - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 03, 2015 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
not specified Benign:2
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Dec 31, 2019 | - - |
Benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Dec 31, 2019 | - - |
Hereditary cancer-predisposing syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 21, 2014 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Hereditary breast ovarian cancer syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | National Health Laboratory Service, Universitas Academic Hospital and University of the Free State | Apr 19, 2022 | - - |
Ataxia-telangiectasia-like disorder Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at